Mats C. Højbjerg Lassen, MD

A Nationwide Factorial Randomized Trial of Electronic Nudges to Patients with Chronic Kidney Disease and Their General Practices for Increasing Guideline-Directed Medical Therapy: The NUDGE-CKD Trial In this nationwide pragmatic, 2x2 factorial implementation trial, electronic…

New episode this week! We discuss pragmatic trial infrastructure in Denmark, implementation science in nephrology and how new approaches to recruitment can improve access, equity and representation in trials #kidneycompass

In the latest episode of #KidneyCompass, @brendonneuen , MBBS, PhD, is joined by @TorBiering MD, MPH, PhD, and @KristofferSkaar, MD, to discuss the design, execution, and implications of the NUDGE-CKD trial. Watch now: hcplive.com/view/kidney-co…

🫀 New paper from the Copenhagen City Heart Study: In 3,792 people 👥 without CVD, ⬆️ remnant cholesterol was 🔗 to worse cardiac function-lower LVEF, impaired GLS, and reduced E/A-stronger than LDL’s effect 🤔 Read the paper: 👉 onlinelibrary.wiley.com/doi/10.1111/ec… @TorBiering @CTCPR_

New paper out 🚨! In high-risk CVD patients, higher education 📚 was linked to a 29% lower risk of cardio-pulmonary 🏥 or ☠️ , compared with low education 📚 level. 📖 read in @JAHA_AHA 👉 ahajournals.org/doi/10.1161/JA… @SheilaHegde @TorBiering @orlyvardeny #CardioTwitter

Simple nudges, strong effects — new RCT by @niklasdj1 @CTCPR_ pub. in JAMA. Behavioral e-letters raised flu vax by up to +13.9 pp. Cost-effective, easy to implement, reduce risk of HF and boosts uptake in high-risk groups, cutting complications and costs. doi.org/10.1001/jama.2…

The very first paper from DANFLU-2 - the largest individually randomized influenza vaccine RCT ever conducted – is officially out in @JAMA_current: An RCT embedded into the recruitment phase testing the impact of recruitment letter design and color scheme. ja.ma/3Gfixqa

Brilliant design @TorBiering. Another example of @CTCPR_ leading rapid cycle randomized clinical trials at scale. @niklasdj1

@CTCPR_ strongly represented at the annual @DCAcademyDK summer meeting: @fwemmer1 on progeria and @drJBorchsenius on psoriasis!

📢 Research shows: Vaginal estradiol use not linked to increased risk of recurrent venous thromboembolism (VTE) in women with prior VTE. ⚖️ Nationwide nested case-control study (n=44,024) 📉 HR for current use: 0.75, p = 0.07 🔗 doi.org/10.1111/ejh.14…

HFimpEF is on the rise, but recovery isn’t the end of the story. Our latest review dives into what we know (and don’t) about its prognosis, treatment, and outcomes jacc.org/doi/full/10.10…

Pooled analysis of obesity and kidney outcomes from 4 HFpEF RCTs now in @JACCJournals 👥 n=16,919 ⬆️ waist circumference ➡️ higher kidney risk🫘🏥 ⬆️ waist-to-height ratio ➡️ higher kidney risk 🫘🏥 But not for BMI 🤔 sciencedirect.com/science/articl… @mvaduganathan @TorBiering

🤩Simultaneous publication for NUDGE CKD trial in @CircAHA #ERA25

#NUDGECKD in @CircAHA #ERA25 by @KristofferSkaar & @TorBiering Nationwide 2x2 Pragmatic Implementation Mega-Trial 👥 n=22,617 🇩🇰 adults w #CKD 🥼n=1540 General practitioners Electronic nudges did not improve uptake of #RASi or #SGLT2i versus usual care ahajournals.org/doi/10.1161/CI…

Rationale and design of NUDGE-CKD: A nationwide randomized factorial trial of electronic nudges for increasing guideline-directed medical therapy in CKD #ERA25 Evaluating if a single electronic letter can increase GDMT use in patients with CKD. sciencedirect.com/science/articl…

📽️ Tor Biering-Sørensen presented the analysis of the primary and secondary endpoint results of the DECODE-CKD at #ACC25. -> medicaldigest.org/scientific-con… @TorBiering @CTCPR_ @ACCmediacenter @ACCinTouch #CardioTwitter

CV hosp rates among older adults in the US compared to Denmark 🇩🇰 🇺🇸 excited to have contributed to this collaborative work with @rkwadhera @TorBiering @mvaduganathan led by Frederikke Berg

Outstanding sci. statement from @HeartDocSadiya @dmljmd et al on primary prev of HF. #PREVENTHF now enrolling, studying ASi+SGLT2i in >11k at risk participants, highlighting a new era for HF PREVENTION! clinicaltrials.gov/study/NCT06677… @mvaduganathan @scottdsolomon @MajaCikes @TorBiering

Risk assessment through HFA/IC-OS stratification tool in breast cancer patients undergoing #HER2-inhibitors: the way for optimizing resource use without compromising cardiovascular safety? jacc.org/doi/10.1016/j.… #JACCCardioOnc #CardioOnc #BCsm #LVEF

In Denmark, CVD affects 11% of the population—but with universal healthcare, registry-based research, and bold public health moves, outcomes are improving. Equity is the next frontier. ❤️ @AM_reimer @Espersen_C @TorBiering ahajournals.org/doi/full/10.11…